Response: Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population

Journal of the National Cancer Institute

Volumn 99, Issue 23, 2007, Pages 1816-1817

  Kerlikowske, Karla ^a,b   Buist, Diana S M ^c   Walker, Rod ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER SCREENING; HORMONAL THERAPY; HUMAN; LETTER; MAMMOGRAPHY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 44449093514     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm212     Document Type: Letter

References (6)

1. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4.
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28 [Epub ahead of print].
3. Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007;25:3437-9.
4. Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61.
5. Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
6. Kerlikowske K, Miglioretti D, Ballard-Barbash R, Weaver D, Buist D, Barlow W, et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 2003;21:4314-21.